Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Braveheart Bio, Inc. (BRVE) Market Cap & Valuation Ratios

Braveheart Bio, Inc. (BRVE) has a market cap of $1.9B, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · read by EquiReason

BRVEBraveheart Bio, Inc.Follow BRVE — free
Drug Manufacturers - General · Healthcare
—
Price chart with a free account
Market cap
1.9B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
12 Nov, in 19 days

Peers

drug manufacturers - general · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
BRVE1.9———————
ABCL3.6—53.0—-3.3%+101%-340%-27%
OGN3.617.61.88.415.7%-2%16%5%
ZLAB2.7—5.2—-5.2%+5%-59%-112%
HCM2.5143.62.2—0.4%-9%-6%-3%
BHC2.4—2.010.4—+10%8%4%
NAMS2.4—241.9—-6.1%-89%—-116%
GENB1.6———————
QURE1.6—42.6—-10.4%+30%——
CMPS1.5———————
GPCR1.5———-14.9%——-30%
Median of these 1080.65.29.4-5.2%+5%-6%-27%

.

Growth vs. price

each dot a company · hover or tap for values

Braveheart Bio, Inc. — questions

What is Braveheart Bio, Inc.'s market cap?
$1.9B.

Every figure on this page comes from Braveheart Bio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.